Greenwood Gearhart’s AbbVie ABBV Stock Holding History

Greenwood Gearhart’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$321K	Buy	1,277 +299	+31%	+$64.3K	0.02%	130
2026 Q1	$213K	Buy	+978	New	+$217K	0.01%	129
2024 Q4	–	Sell	-1,090	Closed	-$215K	–	131
2024 Q3	$215K	Buy	+1,090	New	+$203K	0.02%	102
2024 Q1	–	Sell	-1,256	Closed	-$195K	–	103
2023 Q4	$195K	Buy	+1,256	New	+$183K	0.02%	95

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Greenwood Gearhart's ABBV Position: Q2 2026 in Review

Greenwood Gearhart increased its AbbVie (ABBV) stake by 31% in Q2 2026, buying an estimated $64.3K and bringing the position to 1,277 shares worth $321K. The position accounts for 0.02% of the portfolio, ranked #130.

Greenwood Gearhart first reported a position in ABBV in Q4 2023 and has held it in 4 quarters since. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Greenwood Gearhart held 1,277 shares of AbbVie worth $321K as of Q2 2026.
Greenwood Gearhart bought 299 AbbVie shares in Q2 2026, an estimated $64.3K.
AbbVie made up 0.02% of Greenwood Gearhart's portfolio in Q2 2026, its #130 holding.
Greenwood Gearhart first reported a position in AbbVie in Q4 2023 and has held it in 4 quarters since.
4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Greenwood Gearhart's 13F filing for Q2 2026, filed 24 Jul 2026.